Esketamine Nasal Spray for Treatment-Resistant Bipolar II Depression: A Case Report

• 발행기관: 대한신경정신의학회
• 저자명: Hong-Ci Lin Chia-Yu Chang Ching-Huang Lin Yung-Chih Chiang Cheng-Ho Chang
• 간행물 정보: 『Psychiatry Investigation』제22권 제11호, 1334~1337쪽, 전체 4쪽
• 주제분류: 의약학 > 정신과학
• 파일형태: PDF
• 발행일자: 2025.11.30

국문 초록

This case report discusses a 62-year-old male with treatment-resistant bipolar II depression and hypertension. After poor responses to multiple treatments, an add-on esketamine nasal spray (ESK-NS) was introduced in October 2022. Improvement was seen, and the patient’s depressive episode was nearly remitted during the maintenance phase. However, recurrence was noted when ESK-NS frequency was reduced to once every 2 months, indicating that the dosing frequency should be adjusted cautiously. The patient experienced common side effects, including dissociation, dizziness, and transient hypertension. Nifedipine was offered when his systolic blood pressure exceeded 160 mm Hg, accompanied by headache or dizziness. Blood pressure monitoring was essential throughout ESK-NS treatment. This report highlights esketamine’s potential for bipolar depression treatment and calls for further studies on its cardiovascular effects and proper management.

목차

CASE REPORT

DISCUSSION

Availability of Data and Material

Conflicts of Interest

Author Contributions

ORCID iDs

Funding Statement

Acknowledgments

REFERENCES

키워드

Treatment resistant depression Bipolar depression Esketamine